Back to Search Start Over

Comparing Pain and Depressive Symptoms of Chronic Opioid Therapy Patients Receiving Dose Reduction and Risk Mitigation Initiatives With Usual Care.

Authors :
Thakral, Manu
Walker, Rod L.
Saunders, Kathleen
Shortreed, Susan M.
Parchman, Michael
Hansen, Ryan N.
Ludman, Evette
Sherman, Karen J.
Dublin, Sascha
Von Korff, Michael
Source :
Journal of Pain; Jan2018, Vol. 19 Issue 1, p111-120, 10p
Publication Year :
2018

Abstract

Dose reduction and risk mitigation initiatives have been recommended to reduce opioid-related risks among patients receiving chronic opioid therapy (COT), but questions remain over whether these initiatives worsen pain control and quality of life. In 2014 to 2015, we interviewed 1,588 adult COT patients within a health care system in Washington State and compared those who received dose reduction and risk mitigation initiatives in primary care clinics (intervention) with patients in comparable health care settings without initiatives (control). The primary outcomes were pain assessed using the pain, enjoyment, and general activity (PEG) scale, a 3-item scale to assess global pain intensity and interference, with secondary measures including depression (Patient Health Questionnaire-8 scale). Generalized estimating equations for linear regression models were used to estimate differences in mean scores between intervention and control sites. Estimated differences, adjusted for patient characteristics and weighted for nonresponse, between patients at intervention and control clinics were not clinically significant for the PEG (-.03, 95% confidence interval = -.25 to .19) or Patient Health Questionnaire-8 (-.64, 95% confidence interval = -1.19 to -.08). We found no evidence that COT patients in clinics with dose reduction and risk mitigation initiatives had clinically meaningful differences in pain intensity, interference with activities and enjoyment of life, or depressive symptoms compared with control health care settings.<bold>Perspective: </bold>This article evaluates the effect of dose reduction and risk mitigation initiatives, such as those recently recommended by the Centers for Disease Control and Prevention, to reduce risks associated with COT on global pain and interference, depressive symptoms, and perceived pain relief and bothersomeness of side effects. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
15265900
Volume :
19
Issue :
1
Database :
Supplemental Index
Journal :
Journal of Pain
Publication Type :
Academic Journal
Accession number :
127099903
Full Text :
https://doi.org/10.1016/j.jpain.2017.09.006